Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Current Assets Current Deferred Revenue Current Leases Current Taxes Dividends payables Finished Goods Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deffered Revenue Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Shares Prepaid Assets Property, Plant & Equipment (Net)Raw Materials Receivables Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Daily Values

Growth Metrics

Others

Gyre Therapeutics (GYRE) Preferred Stock Liabilities (2022 - 2023)

Gyre Therapeutics (GYRE) has disclosed Preferred Stock Liabilities for 5 consecutive years, with $64.5 million as the latest value for Q4 2023.

On a quarterly basis, Preferred Stock Liabilities rose 93.72% to $64.5 million in Q4 2023 year-over-year; TTM through Dec 2023 was $64.5 million, a 93.72% increase, with the full-year FY2023 number at $64.5 million, up 93.72% from a year prior.
Preferred Stock Liabilities was $64.5 million for Q4 2023 at Gyre Therapeutics, up from $33.3 million in the prior quarter.
In the past five years, Preferred Stock Liabilities ranged from a high of $64.5 million in Q4 2023 to a low of $33.3 million in Q4 2022.